Get started
Author

Debra Ann Hanks

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
2016 · Fred R. Hirsch, Abigail McElhinny, et al. · Journal of Thoracic Oncology · 1,271
PDF
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
2018 · Karina Kulangara, Nancy Zhang, et al. · Archives of Pathology & Laboratory Medicine · 539
Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx.
2017 · Karina Kulangara, Debra Ann Hanks, et al. · Journal of Clinical Oncology · 88
Comparative analysis of machine learning approaches to classify tumor mutation burden in lung adenocarcinoma using histopathology images
2021 · Apaar Sadhwani, Huang-Wei Chang, et al. · Scientific Reports · 59
PDF
Investigation of PD-L1 expression and response to pembrolizumab (pembro) in gastric cancer (GC) and cervical cancer (CC) using combined positive score (CPS) and tumor proportion score (TPS).
2018 · Karina Kulangara, Lindsay Guerrero, et al. · Journal of Clinical Oncology · 23
A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy Alone
2022 · Monika D. Polewski, Gitte B. Nielsen, et al. · Applied immunohistochemistry & molecular morphology · 21
A machine learning-based approach for the inference of immunotherapy biomarker status in lung adenocarcinoma from hematoxylin and eosin (H&E) histopathology images.
2020 · Cory Batenchuk, Huan-Wei Chang, et al. · Journal of Clinical Oncology · 3
Assay performance of the PD-L1 IHC 28-8 pharmDx assay in squamous cell carcinoma of the head and neck (SCCHN).
2017 · Sara Alvarez, Debra Ann Hanks, et al. · Journal of Clinical Oncology · 2
PD-L1 Detection and Assay Performance in Squamous Cell Carcinoma of the Head and Neck Using PD-L1 IHC 28-8 pharmDx
2017 · S. Alvarez, J. Chan, et al. · Annals of Oncology · 1
PDF
Development of a clinical trial immunohistochemistry (IHC) assay using a novel antibody to CD38.
2017 · Karen Wakamiya, Marsha Hudson, et al. · Journal of Clinical Oncology · 1
Development of a diagnostic PD-L1 immunohistochemical assay for nivolumab therapy in urothelial carcinoma.
2017 · Rose Ann De Los Santos, Josette William, et al. · Journal of Clinical Oncology · 1
AI-enabled virtual hematoxylin and eosin and Masson’s trichrome staining for non-alcoholic fatty liver disease activity scoring from single unstained slide
2023 · Carson McNeil, Pok Fai Wong, et al. · Journal of Hepatology
Abstract LB-218: Pathologist reproducibility of combined positive score (CPS) for the evaluation of PD-L1 in gastric or gastroesophageal junction adenocarcinoma tumors
2018 · Lindsay Guerrero, Karina Kulangara, et al. · Cancer Research
Abstract 4517: Characterization of a standardized immunohistochemical assay for detecting PD-L1 expression in non-small cell lung cancer using anti-PD-L1 clone 73-10
2018 · Darlene Krohn, Mai Nguyen, et al. · Cancer Research
Digital image analysis as an aid in the assessment of the combined positive score in ovarian carcinoma.
2017 · Karina Kulangara, David Calcagno, et al. · Journal of Clinical Oncology
Estrogen receptor positivity improves breast cancer survival prognosis for all underserved ethnic groups except African Americans
2005 · V. Bhatia, E. Roldan, et al. · Journal of Clinical Oncology
Works count: 16
Citation count: 2,009
H-index: 6
I10-index: 6
Year
Topic
Type